ELSO Lancet COVID-19 Article

ANN ARBOR, MI - Sept. 25, 2020 - The Extracorporeal Life Support Organization (ELSO) announced today publication in The Lancet of registry findings examining the treatment of COVID-19 patients with extracorporeal membrane oxygenation (ECMO) support. The results show that for ECMO-supported patients with COVID-19, estimated in-hospital mortality 90 days after ECMO and mortality rates in those with a final disposition of death or discharge were under 40 percent.
Full Press Release
The Lancet Article

COVID-19 Cases on ECMO in the ELSO Registry
Total COVID-19 Cases COVID-19
Suspected or Confirmed
3561
COVID-19
Confirmed Cases
3547
Total counts of COVID-19 confirmed patients and count of COVID-19 suspected but not confirmed by testing.
Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
2631
COVID-19
In-hospital Mortality
45%
COVID-19 ECMO counts by ELSO Chapter
North America2318
Europe789
Asia Pacific55
Latin America148
SWAAC251

FULL COVID-19 REGISTRY DASHBOARD

Disclaimer

Welcome to ELSO

The Extracorporeal Life Support Organization (ELSO) is an international non-profit consortium of health care institutions who are dedicated to the development and evaluation of novel therapies for support of failing organ systems. Crucial is the promotion of a broad multidisciplinary collaboration. The primary mission of the Organization is to maintain a registry of, at least, use of extracorporeal membrane oxygenation in active ELSO centers. As appropriate, registries of other novel forms of organ system support are within the purview of ELSO. Registry data is to be used to support clinical research, support regulatory agencies, and support individual ELSO centers. ELSO provides educational programs for active centers as well as for the broader medical and lay communities.

OUR VISION


Notice:

Guidelines for ECMO in COVID-19 patients

ELSO has prepared an in-depth set of guidelines for ECMO in COVID-19 patients. These have been collaboratively developed by a global team of ECMO experts. The guidelines include: patient selection criteria, cannulation and decannulation strategies, transport on ECMO, PPE and staff protection strategies with ECMO, to ethical dilemmas and quality. ELSO wants to recognize the leadership of Kiran Shekar in chairing the development of these guidelines during a critical time.
Guidelines for ECMO in COVID-19 patients Link

ECMO Capacity Map

ELSO has developed a map that quickly shows ECMO capacity (map: https://www.elso.org/Membership/CenterMap.aspx). Center administrators can update the capacity here: http://www.elso.org/UpdateECMOCapacity) or from the Manage - Manage Center Details section.


Individual Membership

Join the discussion and begin fostering communication and collaboration among professionals who apply advanced technologies in the treatment of refractory organ failure

Individual Membership

Join the discussion and begin fostering communication and collaboration among professionals who apply advanced technologies in the treatment of refractory organ failure

Individual Membership

Join the discussion and begin fostering communication and collaboration among professionals who apply advanced technologies in the treatment of refractory organ failure

Meetings

9th Euro-ELSO Meeting 03/29/2021 - 03/31/2021
Location: London, England
euroelso2020@interplan.de
Posted Date: 03/26/2020
website »

32nd Annual ELSO Conference 09/30/2021 - 10/03/2021
Location: JW Marriott, Indianapolis, IN
Kennethia Banks or Peter Rycus 734-998-6600 kbanks@elso.org
Posted Date: 05/26/2020

ELSO Courses/Workshops